Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18334614 | 0.87 | ITGB1 (0.36) | GAAMT-CO2ALOX5MTNR1AMTNR1B | |
| SCHEMBL18334479 | 0.80 | GAA (0.39) | GAAMT-CO2ALOX5MTNR1AMTNR1B | |
| SCHEMBL18334460 | 0.80 | MTNR1A (0.46) | GAAMTNR1AMTNR1B | |
| SCHEMBL18334587 | 0.77 | ESR1 (0.41) | GAAESR1KCNH2LMNAALDH1A1 | |
| SCHEMBL28091310 | 0.76 | SIGMAR1 (0.38) | MT-CO2ALOX5MTNR1AMTNR1BRAB9A | |
| SCHEMBL18334537 | 0.76 | GAA (0.37) | GAAMT-CO2ALOX5MTNR1AMTNR1B | |
| SCHEMBL18334463 | 0.74 | ESR1 (0.34) | GAAESR1KCNH2LMNAALDH1A1 | |
| SCHEMBL18334574 | 0.71 | MT-CO2 (0.34) | GAAMT-CO2ALOX5MTNR1AMTNR1B | |
| SCHEMBL28091304 | 0.68 | SIGMAR1 (0.36) | GAAMT-CO2ALOX5MTNR1AMTNR1B | |
| SCHEMBL18768138 | 0.66 | ESR1 (0.43) | GAAESR1KCNH2RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3109239-A1 | AMINOPYRAZOLONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107207-A1 | AMINOPYRAZOLONE DERIVATIVE | ATAD5, ATP1A1, TIPRL | GAA 2530/4885ESR1 3521/4885KCNH2 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.